

Special Issue

COVID-19 Vaccines: From Immune Escape to Neutralizing Antibody-Based Therapeutics to Sterilizing Immunity

Message from the Guest Editor

The COVID-19 pandemic has been largely contained thanks to massive deployment of anti-spike vaccines. Different technologies have been in place, but none of them has been convincingly able to induce sterilizing mucosal immunity. Transmission of infection from vaccines to nonresponding immunosuppressed patients at risk for severe COVID-19 demands the development of next-generation mucosal vaccines able to induce sterilizing immunity. Mucosal vaccines come with additional benefits, such as oral route, home self-administration, and no need for needles or refrigeration chains. These manufacturing efforts are nevertheless halted by the ongoing evolution of the spike protein. Clinical experiences with neutralizing antibody-based therapeutics (i.e., anti-RBD monoclonal antibodies and convalescent plasma) have largely contributed to identifying the critical residues within the spike proteins which should be monitored for vaccine resistance.

Guest Editor

Dr. Fabrizio Maggi

1. Department of Medicine and Surgery, University of Insubria, Varese, Italy
2. Laboratory of Virology, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

Deadline for manuscript submissions

closed (25 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/100417

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).